PureTech Health PLC

NASDAQ PRTC

Data sourced from

and

Download Data

PureTech Health PLC Cash and Short-Term Investments for the quarter ending March 31, 2024: USD 328.77 M

PureTech Health PLC Cash and Short-Term Investments is USD 328.77 M for the quarter ending March 31, 2024, a -6.09% change year over year. Cash and Short-Term Investments is the sum of cash and short-term investments, representing the company's liquid assets.

PureTech Health PLC Cash and Short-Term Investments for the quarter ending March 31, 2023 was USD 350.10 M, a -24.83% change year over year.
PureTech Health PLC Cash and Short-Term Investments for the quarter ending March 31, 2022 was USD 465.71 M, a 15.31% change year over year.
PureTech Health PLC Cash and Short-Term Investments for the quarter ending March 31, 2021 was USD 403.88 M.

NASDAQ: PRTC

PureTech Health PLC

CEO	Ms. Daphne Zohar
IPO Date	Nov. 16, 2020
Location	United States
Headquarters	6 Tide Street, Boston, MA, United States, 02210
Employees	90
Sector	Healthcare
Industry	Biotechnology

Description

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Key trends